Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam D Cohen

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Multiple myelomaKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
The Journal of Clinical Investigation|March 22, 2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaAdam D Cohen, Alfred L Garfall, Edward A Stadtmauer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Multiple myeloma, version 1.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Multiple myelomaKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
The Journal of Clinical Investigation|March 22, 2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaAdam D Cohen, Alfred L Garfall, Edward A Stadtmauer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2013
Multiple myeloma, version 1.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-UpThomas Martin, Saad Z Usmani, Jesus G Berdeja, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 12, 2012
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013Kenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Pageof 11